Nexavar (Sorafenib)

DRUG3 trials

Sponsors

GBG Forschungs GmbH, Italian Trial in Medical Oncology, Disruptive Pharma

Conditions

Breast CancerHealthyMetastatic DiseaseRenal Cell Carcinoma

Early Phase 1

A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers

CompletedNCT06797427

Disruptive PharmaHealthy

Start: 2025-02-10End: 2025-03-10Updated: 2025-03-17

Phase 2

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer

CompletedNCT00548899

GBG Forschungs GmbHBreast Cancer

Start: 2007-11-30End: 2011-12-31Updated: 2015-03-09

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)

CompletedNCT00609401

Italian Trial in Medical OncologyMetastatic Disease, Renal Cell Carcinoma

Start: 2006-11-30End: 2008-05-31Updated: 2009-02-26

Related Papers

Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.

2013-09-2420 citations